DR. ROMALA SURENDRAN M.D
Prescription History 1487010849
Internal Medicine - Critical Care Medicine in Neptune, NJ


Quality Rating: 84.47 out of 100 score

NPI Status: Active since January 14, 2016

Contact Information

1945 STATE ROUTE 33
NEPTUNE, NJ
ZIP 07753
Phone: (732) 776-4483

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ROMALA SURENDRAN M.D, an active Critical Care Medicine specialist practicing in Neptune, NJ. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 102 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 25 claims alone.

Medication Index


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 23
30-Day Fills 24.3
Days Supply 594
NJ State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills72.1
Peer Average Days Supply1,826
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.0% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $769.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.47

State Avg Cost Per Claim

$48.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
NJ State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills52.6
Peer Average Days Supply1,554
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.3% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,620.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$506.32

State Avg Cost Per Claim

$612.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
NJ State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills56.1
Peer Average Days Supply1,659
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.8% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,766.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$408.77

State Avg Cost Per Claim

$520.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
NJ State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills37.9
Peer Average Days Supply1,084
Conservative Utilization

This provider writes prescriptions for this formulation 46.7% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,188.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$386.80

State Avg Cost Per Claim

$447.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 750
NJ State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills91.0
Peer Average Days Supply2,721
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.7% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,258.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$690.35

State Avg Cost Per Claim

$863.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ROMALA SURENDRAN M.D provides transparency into local medical care patterns within Neptune, NJ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Critical Care Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.